Wedbush Forecasts Geron’s Q2 Earnings (NASDAQ:GERN)

Geron Co. (NASDAQ:GERN) – Equities researchers at Wedbush boosted their Q2 2025 earnings per share (EPS) estimates for Geron in a research note issued on Wednesday, May 7th. Wedbush analyst R. Driscoll now anticipates that the biopharmaceutical company will post earnings of ($0.02) per share for the quarter, up from their prior estimate of ($0.03). The consensus estimate for Geron’s current full-year earnings is ($0.25) per share. Wedbush also issued estimates for Geron’s Q3 2025 earnings at ($0.02) EPS, Q4 2025 earnings at ($0.01) EPS and FY2025 earnings at ($0.08) EPS.

A number of other equities research analysts also recently commented on the company. HC Wainwright reiterated a “neutral” rating on shares of Geron in a report on Wednesday, March 12th. Scotiabank downgraded Geron from a “sector outperform” rating to a “sector perform” rating and lowered their price target for the stock from $4.00 to $1.50 in a report on Thursday, May 8th. Stifel Nicolaus decreased their price objective on Geron from $8.00 to $4.00 and set a “buy” rating for the company in a report on Thursday, February 27th. B. Riley downgraded Geron from a “buy” rating to a “neutral” rating and decreased their price objective for the stock from $3.50 to $2.00 in a report on Thursday, February 27th. Finally, Barclays reiterated an “overweight” rating and set a $4.00 price objective (down from $9.00) on shares of Geron in a report on Thursday, February 27th. One analyst has rated the stock with a sell rating, three have assigned a hold rating, five have given a buy rating and one has assigned a strong buy rating to the company’s stock. According to MarketBeat, the company presently has a consensus rating of “Moderate Buy” and an average price target of $5.06.

Geron Trading Up 8.5%

Shares of GERN opened at $1.28 on Monday. The company has a quick ratio of 2.74, a current ratio of 2.89 and a debt-to-equity ratio of 0.04. Geron has a 12-month low of $1.17 and a 12-month high of $5.34. The firm has a market capitalization of $815.26 million, a PE ratio of -4.00 and a beta of 0.76. The stock’s fifty day simple moving average is $1.48 and its 200-day simple moving average is $2.70.

Geron (NASDAQ:GERN) last posted its quarterly earnings data on Wednesday, May 7th. The biopharmaceutical company reported ($0.03) EPS for the quarter, topping analysts’ consensus estimates of ($0.04) by $0.01. Geron had a negative return on equity of 67.53% and a negative net margin of 682.48%. The company had revenue of $39.60 million for the quarter, compared to analyst estimates of $49.88 million. During the same quarter in the previous year, the firm earned ($0.07) earnings per share. The business’s revenue was up 12927.3% on a year-over-year basis.

Institutional Inflows and Outflows

Several large investors have recently bought and sold shares of the stock. SBI Securities Co. Ltd. acquired a new stake in shares of Geron in the fourth quarter valued at approximately $28,000. Integrated Wealth Concepts LLC acquired a new stake in Geron during the 4th quarter worth approximately $36,000. Sowell Financial Services LLC acquired a new stake in Geron during the 1st quarter worth approximately $43,000. GF Fund Management CO. LTD. acquired a new stake in Geron during the 4th quarter worth approximately $45,000. Finally, 111 Capital acquired a new stake in Geron during the 4th quarter worth approximately $52,000. 73.71% of the stock is owned by institutional investors and hedge funds.

Geron Company Profile

Geron Corporation, a late-stage clinical biopharmaceutical company, focuses on the development and commercialization of therapeutics for myeloid hematologic malignancies. It develops imetelstat, a telomerase inhibitor that is in Phase 3 clinical trials, which inhibits the uncontrolled proliferation of malignant stem and progenitor cells in myeloid hematologic malignancies for the treatment of low or intermediate-1 risk myelodysplastic syndromes and intermediate-2 or high-risk myelofibrosis.